BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
- Westport, CT, April 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the Company"), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Anthony Amato to the Position of Chief Executive Officer (“CEO”), effective immediately.
- 04/30/2024
|
BioSig Engages Consulting Firm for Business Model Strategies
- BAIPC will work to deploy a series of solutions to transform BioSig's future course BAIPC will work to deploy a series of solutions to transform BioSig's future course
- 04/04/2024
|
BioSig Announces Reduction of its Workforce
- Westport, CT, Feb. 20, 2024 (GLOBE NEWSWIRE) -- -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company, today announced that it has terminated a significant number of its employees and expects to substantially reduce business operations.
- 02/20/2024
|
BioSig's PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases
- Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately 66%. Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately 66%.
- 02/06/2024
|
BioSig Announces Reverse Stock Split
- Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024 Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024
- 01/31/2024
|
BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy
- Westport, CT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced a workforce reduction, intended to reduce annual cash burn by 50%. The Company is reducing its internal workforce, which is expected to be completed by January 31. The Company is also shifting its business model and seeks to partner with organizations for sales distribution and clinical support of its PURE EP™ Platform.
- 01/30/2024
|
BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024
- Westport, CT, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today issued its 2023 letter to shareholders to recap recent achievements and offer insights about the year ahead.
- 12/06/2023
|
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Westport, CT, Nov. 13, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 6,996,922 shares of its common stock, Series A warrants to purchase up to 6,996,922 shares of common stock and Series B warrants to purchase up to 6,996,922 shares of common stock, at a purchase price of $0.3573 per share of common stock and associated warrants.
- 11/13/2023
|
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Westport, CT, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Westport, CT, Nov. 9, 2023 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,996,922 shares of its common stock, Series A warrants to purchase up to 6,996,922 shares of common stock and Series B warrants to purchase up to 6,996,922 shares of common stock, at a purchase price of $0.3573 per share of common stock and associated warrants, in a registered direct offering priced at-the-market under Nasdaq rules.
- 11/09/2023
|
BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI
- IP portfolio includes U.S. and worldwide utility and design patents and pending applications in the U.S., Europe, and Asia-Pacific IP portfolio includes U.S. and worldwide utility and design patents and pending applications in the U.S., Europe, and Asia-Pacific
- 11/01/2023
|
BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model
- BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.
- 08/25/2023
|
BioSig AI Sciences Achieves Infrastructure and Technology progress in Development of Generative AI Platform for Hospitals
- Westport, CT, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today is providing an update since the launch of BioSig's established technology team with external partners and collaborators to advance the research and development of an artificial intelligence (“AI”) medical device platform.
- 08/24/2023
|
BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations
- Cleveland Clinic, the #1 heart center in the Nation, signs on as first subscriber to receive latest software advancements in intracardiac signal visualization Cleveland Clinic, the #1 heart center in the Nation, signs on as first subscriber to receive latest software advancements in intracardiac signal visualization
- 08/23/2023
|
BioSig's PURE EP™ Platform Debuts New Automated Features in First Patient Cases
- Latest Software Release Supports Electrophysiologists with Visualizing Heart Patterns Difficult to Recognize with the Naked Eye Latest Software Release Supports Electrophysiologists with Visualizing Heart Patterns Difficult to Recognize with the Naked Eye
- 08/22/2023
|
BioSig AI Sciences Receives $2.2 Million in Seed Funding to Advance Development of Artificial Intelligence Applications
- Deal to create additional value through subsidiary to advance Artificial Intelligence strategy without dilution to BioSig Technologies Shareholders Deal to create additional value through subsidiary to advance Artificial Intelligence strategy without dilution to BioSig Technologies Shareholders
- 07/25/2023
|
Why Is BioSig Technologies (BSGM) Stock Up 19% Today?
- BioSig Technologies (NASDAQ: BSGM ) stock is rising higher on Thursday as subsidiary BioSig AI Sciences joins Nvidia's (NASDAQ: NVDA ) Inception program. The Inception program is one that Nvidia uses to select companies with promising developments in the AI and data sciences spaces.
- 07/20/2023
|
BioSig AI Sciences Selected for NVIDIA Inception Partnership Program to Support R&D Collaboration on AI Medical Device Platform for Hospitals
- Westport, CT, July 20, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that its subsidiary BioSig AI Sciences, Inc. (BAIS) was selected to join NVIDIA Inception , a program designed to partner with companies revolutionizing industries with advancements in artificial intelligence (AI) and data sciences.
- 07/20/2023
|
BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology
- The foundation of BioSig's (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.
- 06/29/2023
|
BioSig Joins Webull Corporate Connect
- Webull's investor community can now access real-time BioSig investor communications and Q&A Webull's investor community can now access real-time BioSig investor communications and Q&A
- 06/29/2023
|
The Benefits of Investing in Penny Stocks in the Long Term
- Why investing in penny stocks in the long term could be the right choice The post The Benefits of Investing in Penny Stocks in the Long Term appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/11/2023
|
4 Hot Penny Stocks To Buy For Under $1 Before Next Week
- Penny stocks under $1 to watch before next week. The post 4 Hot Penny Stocks To Buy For Under $1 Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/06/2022
|
3 Medical Instruments Stocks With Potential to Outperform
- Here we discuss ShockWave Medical (SWAV), CheckCap (CHEK) and Biosig Technologies (BSGM) that have the potential to outperform their industry going forward.
- 09/08/2022
|
Bluejay Diagnostics (NASDAQ:BJDX), BioSig Technologies (NASDAQ:BSGM) – Sharps Technology And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
- The Dow Jones closed higher by more than 400 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.
- 09/08/2022
|
(BSGM), (LDI) – BioSig Technologies, Reliance Global Group And 2 Other Penny Stocks Insiders Are Aggressively Buying
- U.S. stocks recorded losses for the fourth straight session on Wednesday. Investors, meanwhile, focused on some notable insider trades.
- 09/01/2022
|
BioSig Technologies says Kansas City Heart Institute signs purchase agreement for its PURE EP System
- BioSig Technologies Inc has announced that Kansas City Heart Institute at Overland Park Regional Medical Center in Kansas City, USA, has signed a purchase agreement to acquire its PURE EP System. Following its evaluation of BioSig's PURE EP System, Overland Park Regional Medical Center (OPRMC) has signed an agreement to purchase the technology under the terms of the company's new program.
- 07/07/2022
|
BioSig Technologies gets repeat 'Outperform' tag, $4 price target from Noble Capital
- BioSig Technologies Inc has earned a reiterated ‘Outperform' rating and $4 price target from analysts at Noble Capital days after pricing a public offering that generated proceeds of $2.9 million. The offering was “[a] bit unexpected, timing-wise, but supports PURE EP commercialization,” the firm wrote.
- 06/30/2022
|
BioSig Technologies says it intends to offer shares of its common stock in a "best efforts" underwritten public offering
- BioSig Technologies, Inc. (NASDAQ:BSGM) has said it intends to offer shares of its common stock in a "best efforts" underwritten public offering. BioSig said it intends to use the net proceeds from the offering for the continuation of commercialization activities related to the PURE EP System, including additional support for organizational development, to fund working capital, and for general corporate purposes and other capital expenditures.
- 06/24/2022
|
BioSig Technologies enters deal for Cleveland Clinic to evaluate its PURE EP signal processing platform
- BioSig Technologies, Inc. (NASDAQ:BSGM) said it has entered into an evaluation agreement for its PURE EP System with Cleveland Clinic, its first following the induction of a new commercialization team to accelerate the process from product evaluation to adoption. The medical technology company said Cleveland Clinic, a non-profit multi-specialty academic medical center, will participate in a 60-day evaluation of BioSig's signal processing platform.
- 06/22/2022
|
BioSig: PURE EP Economics Trade Exhausted
- Despite numerous positive updates around its PURE EP segment, the market is agnostic in directional movements on the chart. Whilst the muddy waters on its PURE EP economics have been somewhat cleared, many uncertainties remain.
- 06/14/2022
|
BioSig targets July 1 to launch national PURE EP commercial campaign
- BioSig Technologies Inc plans to kick off a national commercial launch campaign for its PURE EP System on July 1, 2022 following multiple initiatives to accelerate its transition from limited market release to nationwide availability. BioSig has more than 30 qualified leads ahead of the launch and to-date, more than 73 physicians have completed over 2,200 patient cases with the PURE EP System, the company said.
- 05/26/2022
|
BioSig maintains ‘Outperform' rating from Noble Capital as "stronger commercialization efforts” underway for its PURE EP system
- BioSig Technologies Inc drew an ‘Outperform' rating from Noble Capital, which noted that "stronger commercialization efforts” are underway for the company's PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP systems after the first quarter. In a note to clients, Noble Capital analysts observed that BioSig recorded no PURE EP unit sales during the quarter, which was “below our expectations of three units”.
- 05/23/2022
|
BioSig Technologies CEO Kenneth Londoner says the company has made great strides as it accelerates commercial momentum for its PURE EP system
- BioSig Technologies, Inc. (NASDAQ:BSGM) CEO Kenneth Londoner said the company has made great strides on multiple fronts as it accelerates commercial momentum for developing a national installed base of its PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP systems. In a letter to shareholders, the company reported recent highlights including that the PURE EP system has now completed over 2,200 patient cases with 75 physicians at 17 hospitals across the United States, the strengthening of its management team, and the launch of its NOVA-5 software which offers greater customization and smarter workflows with the aim of further driving clinical adoption.
- 05/11/2022
|
BioSig to Present at Heart Rhythm 2022
- Company's conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software Company's conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software
- 04/19/2022
|
BioSig to Present at NobleCon18 Capital Markets Conference
- Westport, CT, April 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, will be presenting at NobleCon18 - Noble Capital Markets' Eighteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida on Wednesday, April 20, 2022 at 9:30 AM ET. Conference attendees will also have the opportuntity to meet BioSig management during breakout sessions scheduled for 1:00 PM ET on Wednesday April 20, 2022.
- 04/07/2022
|
BioSig Technologies completes its previously announced underwritten public offering for proceeds of $3 million
- BioSig Technologies Inc has announced the completion of its previously announced underwritten public offering of 2,611,739 shares of its common stock at a price to the public of $1.15 per share for proceeds of $3 million. The company also said it has issued a cash warrant at $1.40, which if fully exercised will see the company receive another $3 million of cash proceeds.
- 03/23/2022
|
BioSig Technologies to raise $3M in equity financing with family investment office
- BioSig Technologies Inc announced that it has agreed to sell $3 million of its common stock and warrants to a family office, which the company said has deep expertise in small-cap emerging growth investing. BioSig noted the net proceeds from the offering will be used to fund working capital and continue commercialization activities related to the PURE EP System.
- 03/22/2022
|
BioSig Technologies appoints John Sieckhaus as chief operating officer
- BioSig Technologies Inc. has announced that John Sieckhaus will be joining the company as chief operating officer.
- 03/16/2022
|
BioSig Technologies receives boost for its PURE EP technology with award of patent claims
- BioSig Technologies Inc, the medtech group, has announced another boost for its heart monitoring technology, revealing that the US Patent Office had awarded patent claims for its PURE EP noise-filtering technology. The patent application was filed on November 6 last year and describes and claims computer-implemented methods for filtering noise from an input signal.
- 01/26/2022
|
BioSig to Present at the 27th Annual International AF Symposium
- PURE EP (TM) System to be highlighted in a Spotlight Session by DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health PURE EP (TM) System to be highlighted in a Spotlight Session by DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health
- 01/07/2022
|
BioSig to Present at the 24th Annual Virtual Needham Growth Conference
- BioSig exits 2021 having completed more than 1800 patient cases with the PURE EP™ System. BioSig exits 2021 having completed more than 1800 patient cases with the PURE EP™ System.
- 01/06/2022
|
BioSig Technologies looking to unlock the future of bioelectronic medicine
- Using targeted electrical signals to harness the body's natural mechanisms to diagnose and treat a range of diseases Has commercialized its first product, a biomedical signal processing platform called PURE EP To date more than 680 patient cases have been conducted with the PURE EP System across eight clinical sites. What BioSig Technologies does: BioSig Technologies Inc (NASDAQ:BSGM) is working to develop and deliver advanced signal processing solutions that will unlock the future of bioelectronic medicine.
- 12/21/2021
|
BioSig Technologies selects Access Strategy Partners to accelerate commercial sales
- BioSig Technologies Inc has announced the appointment of Access Strategy Partners, Inc (ASPI) to advise the company on the next phase of its commercial roll-out. BioSig said the healthcare management firm is expected to enhance the company's market access strategy as BioSig expands the installation base of its signal processing technology for arrhythmia care.
- 12/21/2021
|
BioSig Technologies expands its clinical footprint in Florida, installs PURE EP System in HCA Healthcare-operated hospital
- BioSig Technologies Inc said that it is installing a PURE EP System for an evaluation at the Hospital Corporation of America (HCA) Healthcare-operated Westside Regional Medical Center in Plantation, Florida. Westside Regional Medical Center is an award-winning, 250-bed hospital recognized for providing a wide array of services to the residents of Broward County, South Florida, and visitors from around the world.
- 12/16/2021
|
BioSig to Host Conference Call on December 21, 2021
- Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET.
- 12/13/2021
|
BioSig Technologies appoints Gray Fleming as chief commercial officer
- BioSig Technologies Inc has announced that Gray Fleming will be joining the company as its chief commercial officer. The Westport, Connecticut-based company said that Fleming will bring over 20 years of experience in the healthcare industry.
- 12/01/2021
|
BioSig Technologies initiates Artificial Intelligence Development Program with Israel-based Technion
- BioSig Technologies Inc said it has entered into a feasibility study with Haifa, Israel-based Technion Research & Development Foundation Ltd. The Westport, Connecticut-based company said that the feasibility program will be led by Joachim Behar, Head of the Artificial Intelligence in Medicine Laboratory (AIMLab) at Technion.
- 11/16/2021
|
BioSig Technologies adds to its growing clinical footprint in Texas
- BioSig Technologies Inc announced that it is installing the company's seventeenth PURE EP system — a computerized system measuring and calculating electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures — for an evaluation at the HCA Healthcare-operated Medical City Heart Hospital in Dallas, Texas. Opened in 2019, Medical City Heart Hospital — a cardiovascular department of Medical City Dallas Hospital — provides the most comprehensive heart and vascular treatment in the Southwest.
- 11/10/2021
|
BioSig Technologies installs its PURE EP system at renowned Boston medical center
- BioSig Technologies Inc has said it is installing its PURE EP system for an evaluation at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. The company noted that BIDMC is a world-class teaching hospital of Harvard Medical School, with more than 4,000 physicians and 35,000 employees.
- 11/09/2021
|
BioSig Technologies looking to unlock the future of bioelectronic medicine
- Using targeted electrical signals to harness the body's natural mechanisms to diagnose and treat a range of diseases Has commercialized its first product, a biomedical signal processing platform called PURE EP To date more than 680 patient cases have been conducted with the PURE EP System across eight clinical sites. What BioSig Technologies does: BioSig Technologies Inc (NASDAQ:BSGM) is working to develop and deliver advanced signal processing solutions that will unlock the future of bioelectronic medicine.
- 11/02/2021
|
Clinical Data Published in the Journal of Cardiovascular Electrophysiology Could Be Important for This Stock
- BioSig Technologies, Inc . (NASDAQ: BSGM) announced that an article titled "Evaluation of a Novel Cardiac Signal Processing System for Electrophysiology Procedures: The PURE EP 2.0 Study" has been published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access as of September 23, 2021, via the Wiley Online Library.
- 10/13/2021
|
BioSig's PURE EP System to be Featured in a Live Patient Case During Annual International Symposium on Ventricular Arrhythmias
- Company's signal processing technology for arrhythmia care to be featured during the event co-hosted by the University of Pennsylvania and The Mount Sinai Hospital Company's signal processing technology for arrhythmia care to be featured during the event co-hosted by the University of Pennsylvania and The Mount Sinai Hospital
- 10/12/2021
|
BioSig Inks Manufacturing Deal with Plexus Corp
- Photo by Anna Shvets from Pexels With the recent successes of its PURE EP™ system underway, BioSig Technologies Inc. (NASDAQ: BSGM) has effectively gone global.
- 10/07/2021
|
BioSig says clinical data acquired by its PURE EP System published in Journal of Cardiovascular Electrophysiology
- BioSig Technologies Inc. has announced that clinical data acquired by its PURE EP System has been published in the Journal of Cardiovascular Electrophysiology.
- 10/04/2021
|
BioSig Technologies selects Wisconsin-based Plexus Corp. as its manufacturing partner
- BioSig Technologies Inc. said it has entered into a manufacturing and professional services agreement with Plexus Corp.
- 09/28/2021
|
BioSig Selects Plexus Corp. as its Manufacturing Partner
- Global leader in complex product design, supply chain, manufacturing, and aftermarket services to support the Company's growth Global leader in complex product design, supply chain, manufacturing, and aftermarket services to support the Company's growth
- 09/28/2021
|
BioSig's PURE EP Aims to Address Unmet Needs of Afib Patients
- Image by PublicDomainPictures from Pixabay An estimated 33.5 million individuals worldwide and nearly 2.7 million people in the U.S. live with an often silent, untreated medical issue.
- 09/23/2021
|
BioSig Technologies appoints medical-device industry executive James Barry as independent board director
- BioSig Technologies Inc, which is commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has announced the appointment of Dr James Barry as an independent board director. The company said Dr Barry has more than 30 years of experience in the medical device industry as an executive and corporate board director.
- 09/21/2021
|
BioSig Technologies, Inc. Appoints Medical Device Industry Leader to its Board of Directors
- James J. Barry, Ph.D. will join as an Independent Director as Company expands clinical footprint with its signal processing technology for arrhythmia care James J. Barry, Ph.D. will join as an Independent Director as Company expands clinical footprint with its signal processing technology for arrhythmia care
- 09/21/2021
|
BioSig Expands in Electrophysiology with St. Elizabeth's Medical Center Evaluation
- Increasing its ever-growing presence in the cardiac electrophysiology space, BioSig Technologies (NASDAQ: BSGM) will be installing one of its new PURE EP systems in St. Elizabeth's Medical Center in Boston for evaluation. Physiological pacing procedures are meant to mimic the heart's normal contraction to have markedly improved clinical and hemodynamic benefits.
- 09/17/2021
|
BioSig to install PURE EP System for evaluation at St. Elizabeth's Medical Center in Boston
- BioSig Technologies Inc said it would install a PURE EP System for evaluation at St. Elizabeth's Medical Center in Boston. The company said it initiated the new evaluation program under the leadership of Dr.
- 09/13/2021
|
BioSig Technologies says to participate in The Mark E. Josephson Twenty-Eight Annual State-of-the-Art Arrhythmia Symposium
- BioSig Technologies, Inc. said it has been invited to participate in The Mark E.
- 08/31/2021
|
BioSig Confirmed as a Participant of The Mark E. Josephson Twenty-Eight Annual State-of-the-Art Arrhythmia Virtual Symposium
- Physician-only event, organized by the University of Pennsylvania, is a tribute to the pioneer of cardiac electrophysiology Physician-only event, organized by the University of Pennsylvania, is a tribute to the pioneer of cardiac electrophysiology
- 08/31/2021
|
BioSig's Signal Processing System for Arrhythmia Care To Be Featured At The Kansas City Heart Rhythm Symposium
- A physician user from a leading medical center of excellence will present the technology and discuss recent clinical data A physician user from a leading medical center of excellence will present the technology and discuss recent clinical data
- 08/19/2021
|
BioSig Technologies looking to unlock the future of bioelectronic medicine
- Using targeted electrical signals to harness the body's natural mechanisms to diagnose and treat a range of diseases Has commercialized its first product, a biomedical signal processing platform called PURE EP To date more than 680 patient cases have been conducted with the PURE EP System across eight clinical sites. What BioSig Technologies does: BioSig Technologies Inc (NASDAQ:BSGM) is working to develop and deliver advanced signal processing solutions that will unlock the future of bioelectronic medicine.
- 08/09/2021
|
BioSig To Host Presentations from Physician Users of its Signal Processing System for Arrhythmia Care during the annual Heart Rhythm 2021 convention
- Confirmed speakers include the largest technology users from Mayo Clinic, Texas Cardiac Arrhythmia Institute, and University of Pennsylvania Confirmed speakers include the largest technology users from Mayo Clinic, Texas Cardiac Arrhythmia Institute, and University of Pennsylvania
- 07/20/2021
|
BioSig Technologies expands Texas clinical footprint for its PURE EP technology for arrhythmia care
- BioSig Technologies Inc (NASDAQ:BSGM) has announced the signing of a new agreement for the clinical evaluation of the company's PURE EP technology for arrhythmia care at Medical City North Hills in North Richland Hills, Texas. As part of the evaluation agreement, Medical City North Hills clinical representatives will provide on-site training and assist with data collection and interpretation and workflow customization for every physician and all electrophysiology lab staff members to ensure optimal user experience.
- 07/13/2021
|
BioSig Latest Installation Broadens Clinical Footprint for its Signal Processing Technology for Electrophysiology
- Texas installation builds as company adds team members to support installations around major metropolitan areas Texas installation builds as company adds team members to support installations around major metropolitan areas
- 07/13/2021
|
BioSig to Host Conference Call to Unblind Clinical Data Collected with its Signal Processing Technology for Arrhythmia Care
- Westport, CT, July 12, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a call to discuss the recent conclusions of its PURE EP(tm) 2.0 study, which enrolled 51 patients at Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, TX, Mayo Clinic Florida Campus in Jacksonville, FL and Massachusetts General Hospital in Boston, MA.
- 07/12/2021
|
BioSig Announces Closing of Public Offering of Common Stock
- Westport, CT, July 07, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the completion of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering were $10 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig.
- 07/07/2021
|
BioSig installs PURE EP system at New York hospital as part of northeast commercial launch
- BioSig Technologies Inc (NASDAQ:BSGM) announced that it has installed its PURE EP ECG signal processing platform system at New York-Presbyterian/Weill Cornell Medical Center in New York. Weill Cornell Medical Center, which began conducting patient cases with the PURE EP System in June 2021, offers one of the most extensive electrophysiology programs in the country, the company said.
- 07/07/2021
|
BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology
- The Company installs its novel medical technology platform for arrhythmia care in a leading Center of Excellence The Company installs its novel medical technology platform for arrhythmia care in a leading Center of Excellence
- 07/07/2021
|
Mayo Clinic Purchases BioSig's PURE EP™ for use at its Phoenix Location
- According to a recently filed 8-k, BioSig Technologies, Inc. (NASDAQ: BSGM) received a new purchase order from the Mayo Foundation for medical education and research. The institution commenced the evaluation of the PURE EP™ System in April 2021.
- 07/06/2021
|
BioSig Technologies Raises $10M Via Equity Issued At $4/Share
- BioSig Technologies Inc (NASDAQ: BSGM) has priced its previously announced underwritten public offering of 2.5 million shares at $4.00 per share, representing a discount of 8% from the last close price of $4.35 on Thursday. The gross proceeds will be approximately $10 million, or roughly $11.5 million, if the underwriter exercises its option to purchase an additional 15% of the number of shares.
- 07/02/2021
|
BioSig announces pricing of its $10M offering of common stock
- BioSig Technologies Inc (NASDAQ:BSGM) has announced the pricing of its underwritten public offering to raise about $10 million. In a statement, the company said it could gain roughly an additional $1.5 million in gross proceeds if the underwriter buys an additional 15% in shares.
- 07/02/2021
|
BioSig Announces Pricing of Public Offering of Common Stock
- Westport, CT, July 02, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced pricing of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering are expected to be approximately $10 million, or approximately $11.5 million if the underwriter exercises its 30-day option to purchase an additional 15% of the number of shares of common stock offered in the public offering in full, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig. The offering is expected to close on July 7, 2021, subject to the satisfaction of customary closing conditions.
- 07/02/2021
|
BioSig Announces Proposed Public Offering of Common Stock
- Westport, CT, July 01, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it has commenced an underwritten public offering of its common stock. BioSig also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 07/01/2021
|
BioSig Completes 1,000 Patient Cases and Expects 1,500 more at the end of 2021
- According to recent reports, the global electroceuticals/bioelectric medicine market is currently worth $16.8 billion and is projected to reach $21.5 billion by 2026, at a compound annual growth rate (CAGR) of 5.0% BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company, unlocks the future of bioelectronic medicine with its PURE EP System™. The company recently increased its procedural volume targets to 15,000 due to accelerated technology usage, after delivering 425 procedures at the end of 2020.
- 06/30/2021
|
BioSig says physicians have completed 1,000 patient cases with its PURE EP system technology across nine US installation sites
- BioSig Technologies Inc (NASDAQ:BSGM) has announced that physicians have completed 1,000 patient cases with its technology across nine installation sites. The company's non-invasive computerized technology, the PURE EP system, aims to drive procedural efficiency and efficacy in electrophysiology.
- 06/30/2021
|
BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology
- The Company recently increased its procedural volume targets due to accelerated technology usage BioSig expands its commercial team to target technology adoption across three strategic regions
- 06/30/2021
|
BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology
- The Company recently increased its procedural volume targets due to accelerated technology usage BioSig expands its commercial team to target technology adoption across three strategic regions
- 06/30/2021
|
BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology
- Westport, CT, June 30, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that physicians have completed 1000 patient cases with its technology across nine installation sites.
- 06/30/2021
|
BioSig's Signal Processing System for Electrophysiology Featured in Two Clinical and Scientific Presentations during the annual Heart Rhythm 2021 convention
- Abstracts are due to be presented by physician users and research investigators from two leading institutions Abstracts are due to be presented by physician users and research investigators from two leading institutions
- 06/22/2021
|
BioSig Technologies to present data from a study of its PURE EP system at Heart Rhythm 2021 in July
- BioSig Technologies Inc (NASDAQ:BSGM) has announced that it will present an exhibit at the Heart Rhythm 2021 convention, held July 28-31 at the Boston Convention and Exhibition Center. The company's executive leadership, and clinical, commercial and engineering teams will host a series of presentations at booth 849 that will showcase the latest clinical data and demonstrate the newest software features of its PURE EP System, the non-invasive Class 2 device that aims to drive procedural efficiency and efficacy in electrophysiology.
- 06/15/2021
|
BioSig Technologies, Inc. to Present at the LD Micro Invitational XI Virtual Event
- Presentation on Tuesday, June 8, 2021, at 5 PM ET Presentation on Tuesday, June 8, 2021, at 5 PM ET
- 06/07/2021
|
BioSig Technologies, Inc. to Present at the Jefferies Virtual Healthcare Conference
- Westport, CT, May 28, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Natasha Drapeau, Executive Vice President of BioSig Technologies, Inc. would be presenting at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021, at 2 pm ET.
- 05/28/2021
|
BioSig Technologies, Inc. to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit
- Westport, CT, May 21, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Ken Londoner, Chairman, and CEO of BioSig Technologies, Inc. will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021. The presentation will be available from 8am EST – 5pm EST on the conference website Oppenheimer MedTech, Tools, & Diagnostics Summit (wsw.com) . The Company will also be available for one-on-one investor meetings.
- 05/21/2021
|
BioSig Technologies looking to unlock the future of bioelectronic medicine
- Using targeted electrical signals to harness the body's natural mechanisms to diagnose and treat a range of diseases Has commercialized its first product, a biomedical signal processing platform called PURE EP To date more than 680 patient cases have been conducted with the PURE EP System across eight clinical sites. What BioSig Technologies does: BioSig Technologies Inc (NASDAQ:BSGM) is working to develop and deliver advanced signal processing solutions that will unlock the future of bioelectronic medicine.
- 05/12/2021
|
BioSig Sees Increased Case Volume from Expanding Base of Medical Centers Using Its Proprietary Signal Processing System
- The Company sees increased technology usage across its installed base and anticipates enrolling to at least 1500 cases by the end of 2021 44 physicians have conducted over 800 arrhythmia patient cases to date
- 05/04/2021
|
BioSig Technologies increases patient case goal to 1,500 procedures by end of 2021
- BioSig Technologies Inc (NASDAQ:BSGM), which is commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has increased its patient case goal to at least 1,500 procedures by the end of 2021. BioSig's non-invasive computerized technology, the PURE EP System, aims to drive procedural efficiency and efficacy in electrophysiology.
- 05/04/2021
|
BioSig Sees Increased Case Volume from Expanding Base of Medical Centers Using Its Proprietary Signal Processing System
- Westport, CT, May 04, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it increased the patient case goal from 1000 to at least 1500 procedures by the end of 2021.
- 05/04/2021
|
BioSig says physicians at Mayo Clinic's campus in Phoenix, Arizona have started using its PURE EP System in patient cases treating cardiac arrhythmias
- BioSig Technologies, Inc. (NASDAQ:BSGM) has announced that physicians at Mayo Clinic's campus in Phoenix, Arizona have started using the company's PURE EP System in patient cases treating cardiac arrhythmias. The 30-day clinical evaluation of the PURE EP System is being conducted by the cardiac electrophysiologists Win-Kuang Shen, Hichan El Masry, Arturo Valverde, and Luis Scott.
- 04/27/2021
|
BioSig's PURE EP(tm) System Evaluated with Patients at Mayo Clinic in Arizona
- Westport, CT, April 27, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the physicians at Mayo Clinic's campus in Phoenix, Arizona have started using the Company's PURE EP(tm) System in the patient cases treating cardiac arrhythmias.
- 04/27/2021
|
BioSig's Cardiac Signal Processing System Now Used At Mayo Clinic's Phoenix Campus
- MedTech company BioSig Technologies, Inc.'s (NASDAQ: BSGM) first commercial product — the PURE EP system — is gaining traction with physicians and patients. What Happened: BioSig's PURE EP system, which is intended to treat cardiac arrhythmias, is now being used by physicians at the Mayo Clinic's campus in Phoenix, Arizona, the company said in a release Tuesday.
- 04/27/2021
|
BioSig taps two regional directors to lead its commercial expansion across southeast and central regions of the US
- BioSig Technologies Inc (NASDAQ:BSGM), which is commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has added two experienced electrophysiology regional directors to lead its commercial expansion across the southeast and central regions of the US. The company said Robert Sandler, who will lead regional sales across Texas, brings more than 25 years of sales experience in medical devices.
- 04/15/2021
|
BioSig Expands Commercial Team in Two Strategic Regions
- Two seasoned MedTech sales executives join the Company to lead regional rollouts of the PURE EP System (TM), an electrophysiology system for arrhythmia procedures Two seasoned MedTech sales executives join the Company to lead regional rollouts of the PURE EP System (TM), an electrophysiology system for arrhythmia procedures
- 04/15/2021
|
BioSig Technologies announces release of the PURE EP Software Version 4
- BioSig Technologies, Inc. (NASDAQ:BSGM) has announced the release of the PURE EP Software Version 4. The latest release builds on the main system capabilities of the PURE EP while improving the overall user experience.
- 04/14/2021
|
BioSig Launches Enhanced Signal Processing Capabilities for Advanced Cardiac Signal Analysis Through its Electrophysiology Platform
- Westport, CT, April 14, 2021 (GLOBE NEWSWIRE) -- The latest release represents the most advanced software version of the PURE EPTM System, signal processing technology for treatments of irregular heartbeats
- 04/14/2021
|
BioSig Technologies completes enrollment in PURE EP 2.0 clinical trial
- BioSig Technologies Inc (NASDAQ:BSGM) said it has completed enrollment in the PURE EP 2.0 clinical trial. The multi-center, prospective clinical trial was conducted at the Texas Cardiac Arrhythmia Institute at St.
- 04/13/2021
|
BioSig Completes Enrollment in the PURE EP 2.0 Clinical Study
- Westport, CT, April 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced it completed enrollment in the PURE EP 2.0 clinical trial.
- 04/13/2021
|
BioSig Invited to Join Alliance for Artificial Intelligence in Healthcare (AAIH)
- Westport, CT, April 09, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it had been invited by, and accepted, an invitation to join the Alliance for Artificial Intelligence in Healthcare (AAIH), following BioSig's major patent awards for its AI-based platform that the Company recently won from the U.S. Patent Office.
- 04/09/2021
|
BioSig Technologies sees its PURE EP System highlighted in new feature article in EP Lab Digest
- BioSig Technologies Inc (NASDAQ:BSGM) has seen its PURE EP System featured in the new edition of leading electrophysiology trade publication, EP Lab Digest. This is the second time that the computerized electrophysiology system has been highlighted in EP Lab Digest in 2021, having been mentioned in a January editorial by EP Lab's editor-in-chief Bradley Knight.
- 04/08/2021
|
EP Lab Digest Features Physician Experience with BioSig's Cardiac Signal Acquisition Technology
- Westport, CT, April 08, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the PURE EP™ System was highlighted in a feature interview for the April issue of EP Lab Digest, a leading industry publication for electrophysiology professionals.
- 04/08/2021
|
BioSig Technologies looking to unlock the future of bioelectronic medicine
- Using targeted electrical signals to harness the body's natural mechanisms to diagnose and treat a range of diseases Has commercialized its first product, a biomedical signal processing platform called PURE EP To date more than 680 patient cases have been conducted with the PURE EP System across eight clinical sites. What BioSig Technologies does: BioSig Technologies Inc (NASDAQ:BSGM) is working to develop and deliver advanced signal processing solutions that will unlock the future of bioelectronic medicine.
- 04/06/2021
|
BioSig Technologies says top-rated leading hospital system has purchased its PURE EP systems for multiple campuses in its national network
- BioSig Technologies, Inc. (NASDAQ:BSGM) has announced that a top-rated leading hospital system has purchased the company's PURE EP systems for multiple campuses in its national network. “We are pleased to expand our commercial installations across this most important healthcare system in multiple states.
- 04/06/2021
|
BioSig lands Commercial Sales to Leading Hospital System
- Westport, CT, April 06, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that a top rated leading hospital system purchased PURE EP™ systems for multiple campuses in their national network.
- 04/06/2021
|
BioSig Technologies, Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference
- Westport, CT, April 05, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Ken Londoner, CEO of BioSig Technologies, will provide a corporate overview and business update at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12th, 2021 at 3 PM ET.
- 04/05/2021
|
BioSig Technologies awarded US patent claims for noise-filtering methods of signal processing technology
- BioSig Technologies Inc (NASDAQ:BSGM) said that US Patent Office has allowed a utility patent covering its PURE EP noise-filtering technology. The medical technology firm, which specializes in commercializing a signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, said the patent describes and claims systems and methods for filtering noise during a quiet period.
- 03/30/2021
|
BioSig Awarded U.S. Patent Claims for the Noise-Filtering Methods for its Signal Processing Technology
- Westport, CT, March 30, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent covering its PURE EP™ noise-filtering technology. The recently allowed patent application number 17/082,564 entitled “SYSTEMS AND METHODS FOR PERFORMING ELECTROPHYSIOLOGY (EP) SIGNAL PROCESSING " was filed on October 28, 2020. The patent describes and claims systems and methods for filtering noise (e.g., a cardiac signal) during a quiet period. In particular, this patent involves filtering out harmonics and noise from an input cardiac signal.
- 03/30/2021
|
BioSig CEO says PURE EP System is “gaining momentum” as it adds new healthcare facilities
- BioSig Technologies Inc (NASDAQ:BSGM) founder, Chairman, and CEO Kenneth L. Londoner told investors on Monday that the commercial adoption of the company's first product called the PURE EP, which measures electrocardiographic signals, is “gaining momentum.
- 03/29/2021
|
BioSig Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021
- Westport, CT, March 29, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company had issued a Letter to Shareholders providing highlights on the Company's recent developments and updates.
- 03/29/2021
|
BSGM Stock Price Increases Over 5% Pre-Market: Why It Happened
- The stock price of BioSig Technologies Inc (NASDAQ: BSGM) increased by over 5% pre-market. This is why it happened.
- 03/25/2021
|
BioSig CEO Kenneth L. Londoner to Present at the Oppenheimer 31st Annual Healthcare Conference
- Westport, CT, March 10, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company has been invited to attend the Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021. Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, will be participating in a virtual fireside chat at 8:00 AM ET. Mr. Londoner will also be available for investor meetings.
- 03/10/2021
|
BioSig CEO Kenneth L. Londoner to Present at the 33rd Annual Virtual ROTH Conference
- Westport, CT, March 09, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it will present at the 33rd Annual Virtual ROTH Conference, being held on March 15-17, 2021. Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. will deliver a Company overview and provide updates on recent progress. Mr. Londoner will also be available for investor meetings.
- 03/09/2021
|
BioSig Technologies says US Patent Office allows utility patent that its subsidiary NeuroClear had exclusively licensed from the Mayo Foundation
- BioSig Technologies, Inc. (NASDAQ:BSGM), has said the US Patent Office has allowed a utility patent that its majority-owned subsidiary NeuroClear Technologies, Inc. had exclusively licensed from the Mayo Foundation for Medical Education and Research.
- 03/04/2021
|
BioSig Awarded U.S. Patent Claims for its NeuroClear™ Subsidiary
- Westport, CT, March 04, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent that its majority-owned subsidiary NeuroClear Technologies, Inc. has exclusively licensed from the Mayo Foundation for Medical Education and Research.
- 03/04/2021
|
BioSig Technologies appoints Brenda Castrodad to lead its Human Resources department
- BioSig Technologies, Inc. (NASDAQ:BSGM) announced Tuesday that it has appointed Brenda Castrodad to lead its Human Resources department. The medical technology company seasoned executive noted that Castrodad brings a wealth of experience in leading organizational development in start-ups and Fortune 500 companies within the life sciences sector.
- 02/16/2021
|
BioSig Appoints Brenda Castrodad to Lead Human Resources
- Seasoned medtech executive to scale up the Company's organizational development upon the increase in demand for the evaluative installations of the PURE EP System™ Seasoned medtech executive to scale up the Company's organizational development upon the increase in demand for the evaluative installations of the PURE EP System™
- 02/16/2021
|
BioSig Technologies says it has entered into three new evaluation agreements for its PURE EP System
- BioSig Technologies, Inc. (NASDAQ:BSGM) said it has entered into three new evaluation agreements for the PURE EP System, its novel electrophysiology (EP) signal acquisition and analysis technology. The group said new clinical sites due to receive BioSig's PURE EP System include New York-Presbyterian/Weill Cornell Medical Center, Michigan Medicine–University Hospital - two centers that account for two of the largest EP programs in the country - and Houston Methodist Hospital.
- 02/10/2021
|
Major Medical Centers Enter into Installation Agreements for Evaluation of BioSig PURE EP™ Systems
- New 90-day evaluation cycles enable hospitals to more rapidly assess the platform technology while also accelerating BioSig's commercial activities New 90-day evaluation cycles enable hospitals to more rapidly assess the platform technology while also accelerating BioSig's commercial activities
- 02/10/2021
|
BioSig CEO Kenneth L. Londoner to Present at the Virtual Investor Conference Small and Microcap Showcase
- Westport, CT, Jan. 27, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it will present at the Virtual Investor Conference Small and Microcap Showcase on February 4, 2021.
- 01/27/2021
|
BioSig to Present at the 26th Annual International AF Symposium
- PURE EP(tm) System to be highlighted in a Spotlight session by G. Joseph Gallinghouse, M.D., Texas Cardiac Arrhythmia Institute PURE EP(tm) System to be highlighted in a Spotlight session by G. Joseph Gallinghouse, M.D., Texas Cardiac Arrhythmia Institute
- 01/15/2021
|
BioSig PURE EP System Featured in the Editorial of EP Lab Digest
- Westport, CT, Jan. 14, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the PURE EP™ System was featured in the January issue of EP Lab Digest.
- 01/14/2021
|
BioSig Deploys Vuzix M400 Smart Glasses to Offer Remote Servicing Capabilities in Compliance with COVID-19 Travel Restrictions
- Industry-leading smart glasses technology expected to enhance the utility of BioSig's PURE EP™ System signal processing platform. Remote servicing intended to enable continued installations, upgrades, and training during COVID-19 travel restrictions and lockdown limitations. Industry-leading smart glasses technology expected to enhance the utility of BioSig's PURE EP™ System signal processing platform. Remote servicing intended to enable continued installations, upgrades, and training during COVID-19 travel restrictions and lockdown limitations.
- 01/13/2021
|
BioSig Conducts First Patient Cases with PURE EP(tm) System at Memorial Hospital of South Bend, Indiana
- PURE EP(tm) system evaluation conducted under the leadership of Cardiologists Vinod Chauhan, M.D. and Deepak Gaba, M.D. Memorial Hospital is nationally recognized for its emphasis on innovation. PURE EP(tm) system evaluation conducted under the leadership of Cardiologists Vinod Chauhan, M.D. and Deepak Gaba, M.D. Memorial Hospital is nationally recognized for its emphasis on innovation.
- 01/12/2021
|
BioSig CEO Kenneth L. Londoner to Present at the Sidoti Winter 2021 Investor Conference
- Westport, CT, Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will be presenting live to a virtual audience at the Sidoti Winter 2021 Investor Conference on Wednesday, January 13, 2021 at 2:30 PM ET.
- 01/06/2021
|
BioSig's Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota
- NeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous system disease NeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous system disease
- 12/18/2020
|
BioSig Announces First Sale Of Cardiac Signal Processing Systems
- BioSig Technologies Inc (NASDAQ: BSGM), a medical device company, announced Friday a commercial milestone with respect to its FDA-approved PURE EP Systems. What Happened: Westport, Connecticut-based BioSig said it sold three PURE EP Systems to St. David's HealthCare of Austin, Texas.
- 12/11/2020
|
BioSig Achieves First Commercial Sale of Three PURE EP Systems
- Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence
- 12/11/2020
|
BioSig CEO Kenneth L. Londoner to Present at the 13th Annual LD Micro Main Event Conference
- Westport, CT, Dec. 10, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will be presenting live to a virtual audience at the 13th Annual LD Micro Main Event Conference on Monday, December 14, 2020 at 10:20 AM ET.
- 12/10/2020
|
BioSig's PURE EP System to Support Live Patient Cases during EPLive 2020
- Company's flagship product to be featured in live patient cases broadcast from the Texas Cardiac Arrhythmia Institute on December 3-4, 2020 Company's flagship product to be featured in live patient cases broadcast from the Texas Cardiac Arrhythmia Institute on December 3-4, 2020
- 11/30/2020
|
BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Business Development Update Conference Call (Transcript)
- BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Business Development Update Conference Call (Transcript)
- 11/19/2020
|
BioSig Announces Completion of PURE EP™ System Installation at New Medical Center
- First Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center First Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center
- 10/29/2020
|
BioSig Issues October 2020 Shareholder Update Letter
- Westport, CT, Oct. 28, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company had issued an October 2020 Letter to Shareholders providing highlights on the Company's recent developments and updates.
- 10/28/2020
|
The Big COVID-19 Update at BioSig Technologies
- BioSig Technologies Inc. (NASDAQ: BSGM) was absolutely crushed on Monday after the company announced that it would halt its midstage coronavirus study.
- 10/26/2020
|
Biosig stock plunges to lead Nasdaq losers after trial of COVID-19 treatment halted
- Shares of Biosig Technologies Inc. plunged 39.0% in active morning trading Monday, enough to pace all Nasdaq decliners, after the medical technology company halted a trial of its COVID-19 treatment given disappointing results. Trading volume was 2.0 million shares, already nearly triple the full-day average of about 693,000 shares.
- 10/26/2020
|
BioSig Technologies: Surprise COVID-19 Vaccine Offers 2 Upside Opportunities For The Price Of 1
- BioSig is two investment opportunities rolled into one. An early-stage electrophysiology play, and a late-stage COVID-19 vaccine candidate.
- 08/17/2020
|
Could The BioSig Technologies, Inc. (NASDAQ:BSGM) Ownership Structure Tell Us Something Useful?
- The big shareholder groups in BioSig Technologies, Inc. (NASDAQ:BSGM) have power over the company. Institutions will...
- 08/17/2020
|
Infectious Diseases Expert Prof. Angus Dalgleish Joins ViralClear’s Scientific Advisory Board
- Westport, CT, Aug. 06, 2020 (GLOBE NEWSWIRE) -- * Expert in Infectious Diseases and Immune Oncology * ViralClear Pharmaceuticals is Currently in Phase 2 Trials with Merimepodib in the Fight Against COVID-19BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced the addition of Professor Angus Dalgleish to its Scientific Advisory Board (SAB). Angus Dalgleish, M.D. is the Foundation Chair of Oncology and Honorary Consultant in Medical Oncology at St. George’s University and Hospital in London and Principal of the Institute of Cancer Vaccines and Immunotherapy. He is a fellow of the Royal College of Physicians both in the UK and Australia, the Royal College of Pathologists, and the Academy of Medical Sciences (UK). Prof. Dalgleish published seminal papers on human immunodeficiency virus (HIV), its receptor on lymphocytes, and its pathogenesis. “We are delighted to welcome Gus to our Scientific Advisory Board with his breadth of experience in developing antiviral drugs,” stated Jerome B. Zeldis, M.D., Ph.D., the acting Chief Medical Officer and Head of ViralClear Pharmaceuticals, Inc. “Gus’ expertise will complement those who are already on the SAB, and we look forward to working with him on this important mission.”Professor Dalgleish said, “I am delighted to join the SAB of ViralClear Pharmaceuticals with my long-term collaborator, friend and colleague Jerry Zeldis with whom I worked with for several years successfully developing lenalidomide and pomalidomide, and I look forward to repeating this success against COVID-19.” ViralClear recently announced the formation of its Scientific Advisory Board to review all aspects of drug discovery and development and advise the Company on its mission to control emerging infections and viral diseases of special interest, including COVID-19. Robin Robinson, Ph.D., the former Head of Biomedical Advanced Research and Development Authority (BARDA), J. Paul Waymack, M.D., ScD, formerly of the Food and Drug Administration and a pioneer antiviral drug developer Michael Sofia, Ph.D. were the first advisors appointed to the Board.About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.About Merimepodib and ViralClear BioSig’s Technologies, Inc (Nasdaq: BSGM) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19. Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400 subjects and patients and an extensive preclinical safety package was completed.Forward-looking StatementsThis press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
- 08/06/2020
|
ViralClear Appoints Dr. Michael Sofia to Its Scientific Advisory Board
- Westport, CT, Aug. 05, 2020 (GLOBE NEWSWIRE) -- * Dr. Sofia is an Inductee in the American Chemical Society Medicinal Chemistry Hall of Fame * ViralClear Pharmaceuticals is Currently in Phase 2 Trials with Merimepodib in the Fight Against COVID-19BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced the addition of Dr. Michael J. Sofia to its Scientific Advisory Board (SAB).Michael Sofia, Ph.D., has introduced numerous drugs into clinical development for the treatment of infectious diseases and inflammatory diseases. He has authored over 110 publications, 15 book chapters and is an inventor on more than 54 US patents. He is the principal inventor of sofosbuvir, currently marketed as the backbone of hepatitis C curative therapies Sovaldi(R), Harvoni(R), Epclusa(R) and Vosevi(R). Dr. Sofia has received numerous recognitions, including the 2016 Lasker-Debakey Award in Clinical Medical Research and induction in the American Chemical Society Medicinal Chemistry Hall of Fame. Currently, Dr. Sofia is a Co-founder and Chief Scientific Officer of Arbutus Biopharma, Inc., a company focused on the discovery and development of therapies to cure hepatitis B.“With Mike’s addition to our Scientific Advisory Board, we believe that we have a very well rounded group of experts who can provide ViralClear with guidance on how to best proceed in addressing the current COVID-19 pandemic and other significant viral infections of special interest,” stated Jerome B. Zeldis, M.D., Ph.D., the acting Chief Medical Officer and Head of ViralClear Pharmaceuticals, Inc.Dr. Sofia commented, “I am excited to join the Scientific Advisory Board of ViralClear. The COVID-19 pandemic has called the drug development community to action to find therapies that can combat this disease. ViralClear’s merimepodib is a novel agent with a new mechanism of action that has the potential to help address this pandemic now. I am eager to bring my expertise in antiviral drug development to help ViralClear in its efforts to develop merimepodib for the fight against COVID-19.”ViralClear recently announced the formation of its Scientific Advisory Board. The goal of the SAB is to review all aspects of drug discovery and development and advise ViralClear on its mission to control emerging infections and viral diseases of special interest, including COVID-19. Robin Robinson, Ph.D., the former Head of Biomedical Advanced Research and Development Authority (BARDA), and J. Paul Waymack, M.D., ScD, formerly of the Food and Drug Administration, were the first advisors appointed to the SAB.About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).The Company’s first product, PURE EP (tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. About Merimepodib and ViralClear BioSig’s Technologies, Inc (Nasdaq: BSGM) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19. Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400 subjects and patients and an extensive preclinical safety package was completed.Forward-looking StatementsThis press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
- 08/05/2020
|
LD Micro - Announces Preliminary List of Presenters for the LD-500.
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
BioSig Installs PURE EP(tm) System at Massachusetts General Hospital | MarketScreener
|
BioSig Installs PURE EP(tm) System at Massachusetts General Hospital
- Patient cases are set to commence in AugustWestport, CT, Aug. 04, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its PURE EP(tm) System at Massachusetts General Hospital (MGH) as part of an expanding clinical study.The PURE EP(tm) System evaluation and data collection at MGH will commence under the leadership of investigator Moussa Mansour M.D., Director of MGH’s Cardiac Electrophysiology Laboratory and Atrial Fibrillation Program. “Bringing our technology to a major EP institution on the east coast is a definite milestone in our clinical development. We look forward to working with Dr. Mansour and the entire MGH team as we pursue our mission of bringing advanced signal processing solutions to the field of electrophysiology,” commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. BioSig is currently conducting patient cases under the clinical study titled, “Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study)” at Texas Cardiac Arrhythmia Research Foundation (TCARF) in Austin, Texas and Mayo Clinic in Jacksonville, Florida. The Shareholder Letter issued by the Company on April 17, 2020, announced that it received Institutional Review Board approvals to install its PURE EP(tm) System at several medical centers across the country for evaluation. All of these centers are high-volume clinical sites regarded for their work with new technologies.“The market for atrial fibrillation is starting to open up again as patient cases are crucial for healthcare outcomes”, said Londoner. About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).The Company’s first product, PURE EP (tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.Forward-looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
- 08/04/2020
|
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
- 08/04/2020
|
BioSig Awarded CAGE Code by the Systems for Award Management (SAM)
- Company moves forward with the qualification to bid for contacts, grants and to do business with the U.S. governmentWestport, CT, Aug. 03, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company has been awarded its Commercial and Government Entity (CAGE) code by the Systems for Award Management (SAM). The CAGE code is required to do business operations with the federal government.BioSig, along with its subsidiary ViralClear, are now registered to conduct business with the U.S. government and can be sought out by government agencies for contracts that fit the Company. The CAGE code also includes the ability to apply and be awarded government contracts, assistance and grant programs.About SAM The System for Award Management (SAM) is a federal government owned and operated free website that consolidates the capabilities in Central Contractor Registration (CCR)/FedReg, Online Representations and Certifications Applications (ORCA) and the Excluded Parties List System (EPLS). Both current and potential government vendors are required to register in SAM in order to be awarded contracts by the government. SAM allows government agencies and contractors to search for companies based on ability, size, location, experience, ownership, and more. SAM allows users to search for firms certified by the SBA under the 8(a) Development and Hubzone Programs. SAM validates the vendor's information and electronically shares the secure and encrypted data with the federal agencies' finance offices to facilitate paperless payments through electronic funds transfer (EFT). Additionally, SAM shares the data with government procurement and electronic business systems.About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.About ViralClear Pharmaceuticals, Inc. and Merimepodib (MMPD) BioSig’s Technologies, Inc (Nasdaq: BSGM) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19. Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400 subjects and patients and an extensive preclinical safety package was completed.Forward-looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
- 08/03/2020
|
BioSig Technologies to Present at the Proactive Investors One2One Virtual Event on August 4, 2020
- Westport, CT, July 30, 2020 (GLOBE NEWSWIRE) -- * Update on the PURE EP(tm) System installations and commercial progress * Update on Phase 2 clinical study of merimepodib in combination with remdesivir in adult patients with advanced COVID-19BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will present at the Proactive Investors One2One Virtual Event on August 4, 2020. Event: Proactive Investors One2One Virtual Event Date: Tuesday, August 4, 2020 Time: 1 PM ET Registration link: https://www.proactiveinvestors.com/register/event_details/269 For more information on the presentation please contact Andrew Ballou, Vice President, Investor Relations at aballou@biosigtech.com.About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.About ViralClear Pharmaceuticals, Inc. and Merimepodib (MMPD) BioSig’s Technologies, Inc (Nasdaq: BSGM) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19. Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400 subjects and patients and an extensive preclinical safety package was completed.Forward-looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
- 07/30/2020
|
Stocks To Watch: Big Focus On Big Tech
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 07/25/2020
|
BioSig Technologies to Participate in LD Micro’s Zooming with LD
- Chairman and CEO Kenneth L. Londoner to provide an update on the commercial rollout of PURE EP(tm) System, clinical development of BioSig’s pharmaceutical subsidiary and conduct virtual one-on-one meetings with investorsWestport, CT, July 23, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced today that the Company would be presenting at LD Micro’s Zooming with LD on Monday, July 27, 2020. Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will be presenting an overview of the Company as well as recent developments and key highlights, including progress with PURE EP(tm) system installations, the implementation of a stockholders rights plan, BioSig’s subsidiary ViralClear Pharmaceuticals, Inc.’s (ViralClear) creation of a Scientific Advisory Board and enrollment of its Phase II clinical study of merimepodib in combination with remdesivir in adult patients with advanced COVID-19. “With our stock up 34% year-to-date and the strongest balance sheet in the Company’s history, we are well-positioned for continuous value creation on behalf of our shareholders. Despite the challenging environment, we remained steadfast in securing hospital support for the PURE EP(tm) System’s ongoing and future installations. Our pharmaceutical subsidiary ViralClear sees a steady patient enrollment across many hospital sites. We are pleased to reconnect with the LD Micro investor community and look forward to reporting on our progress,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. The BioSig presentation will take place virtually over Zoom on Monday, July 27th. Mr. Londoner will also be available for one-on-one meetings with investors on the same day. To register for this 8 am PST presentation, click here.About LD Micro LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event). In 2015, LD Micro launched ldmicro.com as a portal to provide exclusive intraday information on the entire sector, including the first pure micro-cap index (LDMi) which covers stocks in North America with market capitalizations between $50 million to $300 million. About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.About ViralClear Pharmaceuticals, Inc. and Merimepodib (MMPD) BioSig Technologies, Inc.’s (BSGM) subsidiary, ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19. Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400 subjects and patients and an extensive preclinical safety package was completed. A manuscript titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro”, was submitted to an online peer-reviewed life sciences journal. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. This article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.Forward-looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
- 07/23/2020
|
ViralClear Announces Formation of Its Scientific Advisory Board
- Westport, CT, July 20, 2020 -- BioSig Subsidiary Enlists Seasoned Professionals in Emerging Infectious Diseases and Regulatory Development to Its Advisory BoardViralClear.
- 07/20/2020
|
BioSig Technologies to Participate in the B Riley FBR Virtual Infectious Disease Summit
- Westport, CT, July 17, 2020 -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical.
- 07/17/2020
|
BIOSIG TECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
BioSig Technologies, Inc. Adopts Stockholder Rights Agreement
- Westport, CT, July 16, 2020 -- Amended Rights Agreement designed to assure stockholders receive fair and equal treatment in the event of an unsolicited takeoverProvides a.
- 07/16/2020
|
'Zooming with LD' to Feature 10 Distinct Companies July 20th-31st
- LOS ANGELES, CA / ACCESSWIRE / July 16, 2020 / LD Micro today announced that it will be hosting ten companies over the final two weeks of July, with a group presentation in the morning, followed by private ...
- 07/16/2020
|
BioSig Technologies, Inc. Adopts Stockholder Rights Agreement
- Westport, CT, July 16, 2020 -- Rights Agreement designed to assure stockholders receive fair and equal treatment in the event of any proposed takeover Provides a guard against.
- 07/16/2020
|
Antivirals In The COVID-19 Space
- A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.
- 07/13/2020
|
Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites
- Westport, CT, July 13, 2020 -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company") and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced the.
- 07/13/2020
|
Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites
- Adult patients hospitalized with COVID-19 are enrolled in Austin, TX, Rochester, MN, Jacksonville, FL, and Scottsdale, AZ
- 07/13/2020
|
BioSig Submits Application to Systems for Award Management (SAM) with U.S. Government
- Westport, CT, July 10, 2020 -- BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal.
- 07/10/2020
|
ViralClear Pharmaceuticals Partners With Albany Molecular Research Inc. (AMRI) on the Manufacture of Merimepodib Active Pharmaceutical Ingredient in Development for the Potential Treatment of COVID-19
- ViralClear, supported by AMRI, is undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2.
- 07/08/2020
|
Antivirals Rather Than Vaccines For COVID-19 (NASDAQ:BCRX)
- The likelihood appears slim of an adequately effective and widely available vaccine being in commercial use before H2 2021.
- 07/07/2020
|
BIOSIG TECHNOLOGIES, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors
- Westport, CT, July 01, 2020 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical.
- 07/01/2020
|
BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering
- The gross proceeds to the Company from this offering were $17.5 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to support commercialization, for working capital and general corporate purposes.
- 06/29/2020
|
BIOSIG TECHNOLOGIES, INC. : Other Events, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
BioSig Technologies Sees Unusually High Options Volume (NASDAQ:BSGM)
- BioSig Technologies Inc (NASDAQ:BSGM) was the recipient of some unusual options trading activity on Wednesday. Traders bought 949 put options on the company. This is an increase of 1,296% compared to the average volume of 68 put options. Shares of NASDAQ:BSGM opened at $7.67 on Friday. The firm’s 50-day simple moving average is $10.46 and […]
- 06/26/2020
|
Why BioSig Technologies Is Plunging Today | The Motley Fool
- The company announced a common stock offering.
- 06/24/2020
|
Dow Keeps Tumbling, Nasdaq Set to Snap Win Streak - Schaeffer's Investment Research
- Stocks are extending their morning losses as the Nasdaq looks to snap its eight-day winning streak while the VIX pivots higher
- 06/24/2020
|
BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering
- The gross proceeds to the Company from this offering are expected to be $17.5 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to support commercialization and for working capital and general corporate purposes.
- 06/24/2020
|
Los índices de Estados Unidos cierran a la baja; el Dow Jones Industrial Average cae un 2,72%
- Los índices de Estados Unidos cierran a la baja; el Dow Jones Industrial Average cae un 2,72%
- 06/24/2020
|
ViralClear Partners with Catalent on Potential Treatment for COVID-19
- Westport, CT, June 22, 2020 -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that.
- 06/22/2020
|
ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19
- Westport, CT, June 17, 2020 -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that.
- 06/17/2020
|
BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Phase II Human Trials for Broad-Spectrum Oral Anti-Viral for Treatment of COVID-19 (Transcript)
- Start Time: 11:00 End Time: 11:47 BioSig Technologies, Inc. (NASDAQ:BSGM) Special Call June 09, 2020, 11:00 AM ET Company Participants Ken Londoner - Chairman a
- 06/09/2020
|
Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19
- Westport, CT, June 08, 2020 -- Company to provide updates on the initiation of human trials for treatment of adult hospitalized patients with COVID-19Phase II clinical trial.
- 06/08/2020
|
Anavex Alzheimer's Progress, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:AVXL)
- Anavex progresses with its ANAVEX 2-73 trial. BioSig adds to its patent portfolio. Inovio's COVID-19 vaccine candidate supply line in trouble.
- 06/07/2020
|
ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19
- The hospital is part of St. David’s HealthCare, one of the largest healthcare systems in Texas. The Company intends to commence its Phase II clinical trial for merimepodib, its broad-spectrum oral anti-viral candidate for the treatment of COVID-19 in adult patients in the coming weeks.
- 06/05/2020
|
BioSig Technologies's PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions
- Westport, CT, Jun 04, 2020 (GLOBE NEWSWIRE via COMTEX) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company...
- 06/04/2020
|
BioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions
- Westport, CT, June 04, 2020 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical.
- 06/04/2020
|
BioSig Technologies Expands Intellectual Property Portfolio
- Westport, CT, June 03, 2020 -- U.S. Patent and Trademark Office awards Company additional patent for PURE EP™ System Five patent applications filed by ViralClear.
- 06/03/2020
|
ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-viral Candidate for Treatment of COVID-19
- Westport, CT, June 01, 2020 -- Company to provide updates on the initiation of human trials for treatment of adult hospitalized patients with COVID-19Phase II clinical trial.
- 06/01/2020
|
COVID-19 Drug and Vaccine Pipeline Status Report - Research; Pre-Clinical; Phase 1, 2 & 3 Drug Candidates - ResearchAndMarkets.com
|
Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael R. Dougherty to the Board of Directors of its majority-owned
- 05/28/2020
|
Coronavirus pharma news roundup – 22/05/20 -
- Trials for vaccines and drugs to fight coronavirus dominated the news this week as funding ramped up and several pharma firms announced positive signs from their studies. Here are the biggest COVID-19 stories of the past seven days
- 05/22/2020
|
ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib
- Westport, CT, May 20, 2020 -- Funding completed in subsidiary without dilution to BioSig common stockPhase II human trials for merimepodib, a broad-spectrum oral anti-viral.
- 05/20/2020
|
FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClear’s Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19, to Proceed
- Westport, CT, May 18, 2020 -- Phase II clinical trial expected to be conducted at multiple centers in the United States, including three Mayo Clinic sites under the leadership.
- 05/18/2020
|
ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-CoV-2, the Cause of COVID-19
- BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro” was published by F1000 Research, an online peer-reviewed life sciences journal publishing program in biology and medicine, while it is undergoing peer review. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, Timothy Wanninger, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author.
- 05/14/2020
|
6 Stocks To Watch: ABBV, FSLY, GDOT, PTGX, SIEN, UNFI
- Stocks Analysis by Harry Boxer covering: Novavax Inc, Overstockcom Inc, United Natural Foods Inc, B&G Foods Inc. Read Harry Boxer's latest article on Investing.com
- 05/13/2020
|
Global Biomedical Sensor Market Analysis 2020: Key Market Developments and Financials of Key Players - ResearchAndMarkets.com
|
Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc.
- Mr. Schmertzler has been the Chairman of the board of directors of PTC Therapeutics, Inc. since 2004, where he was a founding institutional investor. Mr. Schmertzler is currently the independent director of Lehman Commercial Paper, Inc., the largest subsidiary of the liquidating post-bankruptcy Lehman Brothers estate.
- 05/07/2020
|
Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
- Westport, CT, May 05, 2020 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Dennis Purcell to the Board of Directors of its.
- 05/05/2020
|
Could This Under-the-Radar Biotech Piggyback on Gilead's Remdesivir Success?
- You've probably heard by now of Gilead's promising COVID-19 drug, remdesivir. But there's another experimental drug that just might capture investors' attention in the near future.
- 05/05/2020
|
BioSig Resumes Clinical Activities with PURE EP System
- Westport, CT, May 01, 2020 -- Clinical support staff to return to perform elective procedures at Texas Cardiac Arrhythmia Institute as of May 4, 2020Company reconfirms its.
- 05/01/2020
|
ViralClear Submits In Vitro Data on Merimepodib and Remdesivir Synergistic Activity Against the COVID-19 Novel Coronavirus to a Peer-Reviewed Journal
- Westport, CT, April 30, 2020 -- BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination with.
- 04/30/2020
|
Why BioSig's Coronavirus Drug Likely Won't Work
- BioSig’s (BSGM) acquisition of a new drug, Vicromax, has caused the stock to go on a strong rally. However, Vicromax is a repurposed drug, not a targeted drug.
- 04/29/2020
|
Contrasting Viewray (NASDAQ:VRAY) and BioSig Technologies (NASDAQ:BSGM)
- Viewray (NASDAQ:VRAY) and BioSig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation. Profitability This table compares Viewray and BioSig Technologies’ net margins, return on equity and return on […]
- 04/29/2020
|
6 Stocks To Watch: AMC, BLDR, CREX, KURA, NGL, RRGB
- Stocks Analysis by Harry Boxer covering: MGM Resorts International, Fluor Corporation, Builders FirstSource Inc, Avadel Pharmaceuticals PLC. Read Harry Boxer's latest article on Investing.com
- 04/29/2020
|
The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) * AstraZeneca plc (NYSE: AZN) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Avadel Pharmaceuticals PLC
- 04/28/2020
|
BioSig's CEO On Why The Medtech Company Bought An Antiviral Candidate To Fight Coronavirus: 'This Drug Is Really Far Along'
- In February, when the first coronavirus-infected cruise goers came home to the U.S., the biodefense lab in Galveston pulled from its freezer one of five antiviral drug...
- 04/28/2020
|
BioSig to Host Conference Call on Recent Developments of Subsidiary ViralClear and its Broad-Spectrum Oral Anti-Viral Candidate Merimepodib for the Treatment of COVID-19
- Westport, CT, April 24, 2020 -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it will be hosting an investor briefing to provide an.
- 04/24/2020
|
BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19
- Westport, CT, April 24, 2020 -- In vitro studies demonstrated decrease of viral production by over 98%Upon approval, clinical trial to be conducted at Mayo Clinic under the.
- 04/24/2020
|
BioSig up 10% on encouraging data on COVID-19 antiviral
- BioSig Technologies (BSGM +10%) is up out the gate on the heels of results from laboratory studies comparing the antiviral activity of subsidiary ViralClear's merimepodib to Gilead Sciences' (GILD +2.
- 04/23/2020
|
ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research
- Westport, CT, April 23, 2020 -- Merimepodib is shown to decrease viral production of COVID-19 coronavirus more than remdesivir at clinically meaningful drug concentrations in.
- 04/23/2020
|
6 Stocks To Watch: Snap Jumps As Logistics Partners Explodes Higher
- Stocks Analysis by Harry Boxer covering: Apache Corporation, Mallinckrodt, Kirkland Lake Gold Ltd, Delek Logistics Partners LP. Read Harry Boxer's latest article on Investing.com
- 04/23/2020
|
Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
- Westport, CT, April 21, 2020 -- Former senior executive at AstraZeneca and pharmaceutical industry expert to join as Independent Director The Company is developing Vicromax(tm).
- 04/21/2020
|
Artificial Intelligence is Molding Life on Earth | Coinspeaker
- Here are some of the most awesome ways in which artificial intelligence is changing life as we know it today.
- 04/21/2020
|
BioSig Subsidiary ViralClear Submits Application for Vicromax™ Through FDA’s Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials
- On March 31, 2020, the FDA created the Coronavirus Treatment Acceleration Program (CTAP), a special emergency program for possible therapies, using every available method to move new treatments to patients as quickly as possible. The FDA continues to support clinical trials that are testing new treatments for COVID so that they gain valuable knowledge about their safety and effectiveness.
- 04/21/2020
|
BioSig Issues April 2020 Shareholder Update Letter
- Westport, CT, April 17, 2020 -- Information on the progress of our subsidiary ViralClear Pharmaceuticals and Vicromax(tm) – a broad-spectrum orally administered anti-viral.
- 04/17/2020
|
New startup with local ties testing compound with Mayo Clinic to ‘starve’ COVID-19
- The startup's CEO is a former Merck executive who previously led two life sciences companies in the Philadelphia suburbs.
- 04/17/2020
|
BioSig Technologies (NASDAQ:BSGM) Stock Rating Upgraded by Zacks Investment Research
- BioSig Technologies (NASDAQ:BSGM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, Zacks.com reports. The firm currently has a $5.50 target price on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 7.63% from the company’s current price. According to Zacks, […]
- 04/17/2020
|
BioSig Technologies (NASDAQ:BSGM) versus Viewray (NASDAQ:VRAY) Head-To-Head Survey
- Viewray (NASDAQ:VRAY) and BioSig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. Institutional and Insider Ownership 91.7% of Viewray shares are held by institutional investors. Comparatively, 13.9% of […]
- 04/17/2020
|
74 Biggest Movers From Friday
- Gainers
BioSig Technologies, Inc. (NASDAQ: BSGM) shares gained 42.4% to close at $5.14 on Friday. BioSig is expected to host telebriefing on development updates regarding...
- 04/06/2020
|
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.69%
- U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.69%
- 04/03/2020
|
Gaming and Leisure Properties trading resumes GLPI
- Gaming and Leisure Properties trading resumes GLPI
- 03/30/2020
|
Sinclair Broadcast trading resumes SBGI
- Sinclair Broadcast trading resumes SBGI
- 03/30/2020
|
NASDAQ market internals summary $NSD
- NASDAQ market internals summary $NSD
- 03/30/2020
|
MGM Growth Properties participates in a conference call with JPMorgan MGP
- MGM Growth Properties participates in a conference call with JPMorgan MGP
- 03/30/2020
|
Raytheon, Missile Defense Agency sign $2B Standard Missile-3 contract RTN
- Raytheon, Missile Defense Agency sign $2B Standard Missile-3 contract RTN
- 03/30/2020
|
Cheesecake Factory put volume heavy and directionally bearish CAKE
- Cheesecake Factory put volume heavy and directionally bearish CAKE
- 03/30/2020
|
NYSE market internals summary $NYE
- NYSE market internals summary $NYE
- 03/30/2020
|
Microsoft sees 775% usage jump in cloud services regions with 'shelter in place' MSFT
- Microsoft sees 775% usage jump in cloud services regions with 'shelter in place' MSFT
- 03/30/2020
|
U.S. pending home sales rose 2.4% to 111.5 in February
- U.S. pending home sales rose 2.4% to 111.5 in February
- 03/30/2020
|
Fly Intel: Top five analyst downgrades MMM;HLT;MAR;DBI;BWA;MDT
- Fly Intel: Top five analyst downgrades MMM HLT MAR DBI BWA MDT
- 03/30/2020
|
Fly Intel: Top five analyst initiations BSGM;LLNW;ATSG;CNCE;GFL
- Fly Intel: Top five analyst initiations BSGM LLNW ATSG CNCE GFL
- 03/30/2020
|
Benitec Biopharma abbiybces Supreme Court of Queensland approval for redomicile BNTC
- Benitec Biopharma abbiybces Supreme Court of Queensland approval for redomicile BNTC
- 03/30/2020
|
Fly Intel: Top five analyst upgrades GOOGL;GOOG;AMGN;PG;MDLZ;NKE
- Fly Intel: Top five analyst upgrades GOOGL GOOG AMGN PG MDLZ NKE
- 03/30/2020
|
The Brookings Institution to hold a discussion on COVID-19 and the Economy
- The Brookings Institution to hold a discussion on COVID-19 and the Economy
- 03/30/2020
|
Facebook strikes deal to buy AR displays made by Plessey, The Information says AAPL;FB
- Facebook strikes deal to buy AR displays made by Plessey, The Information says AAPL FB
- 03/30/2020
|
Louisiana Governor to hold news conference
- Louisiana Governor to hold news conference
- 03/30/2020
|
Gilead call volume above normal and directionally bullish GILD
- Gilead call volume above normal and directionally bullish GILD
- 03/30/2020
|
Western Asset Mortgage downgraded to Neutral from Buy at BofA WMC
- Western Asset Mortgage downgraded to Neutral from Buy at BofA BofA WMC
- 03/30/2020
|
COVID-19 impact puts even more focus on Moderna's vaccines, says Roth Capital MRNA
- COVID-19 impact puts even more focus on Moderna's vaccines, says Roth Capital Roth Capital MRNA
- 03/30/2020
|
Carvana says receives voluntary request from SEC requesting information CVNA
- Carvana says receives voluntary request from SEC requesting information CVNA
- 03/30/2020
|
Pending Home Sales Index data reported
- Pending Home Sales Index data reported
- 03/30/2020
|
Medtronic reports Onyx ONE Clear Study met primary endpoint MDT
- Medtronic reports Onyx ONE Clear Study met primary endpoint MDT
- 03/30/2020
|
Carvana offering provides additional liquidity safety net, says Baird CVNA
- Carvana offering provides additional liquidity safety net, says Baird Baird CVNA
- 03/30/2020
|
Granite Point Mortgage falls -22.6% GPMT
- Granite Point Mortgage falls -22.6% GPMT
- 03/30/2020
|
Redwood Trust falls -25.3% RWT
- Redwood Trust falls -25.3% RWT
- 03/30/2020
|
Invesco Mortgage falls -28.7% IVR
- Invesco Mortgage falls -28.7% IVR
- 03/30/2020
|
Nordic American Tankers rises 16.7% NAT
- Nordic American Tankers rises 16.7% NAT
- 03/30/2020
|
Owens & Minor rises 40.0% OMI
- Owens & Minor rises 40.0% OMI
- 03/30/2020
|
Itau Corpbanca rises 23.6% ITCB
- Itau Corpbanca rises 23.6% ITCB
- 03/30/2020
|
Bellerophon announces $15.3M registered direct offering priced at-the-market BLPH
- Bellerophon announces $15.3M registered direct offering priced at-the-market BLPH
- 03/30/2020
|
Penn National put volume heavy and directionally bearish PENN
- Penn National put volume heavy and directionally bearish PENN
- 03/30/2020
|
Argus research director to hold an analyst/industry conference call
- Argus research director to hold an analyst/industry conference call
- 03/30/2020
|
Park Hotels & Resorts trading resumes PK
- Park Hotels & Resorts trading resumes PK
- 03/30/2020
|
Early notable gainers among liquid option names on March 30th CAH;MCK;ABT;SRCL;JNJ
- Early notable gainers among liquid option names on March 30th CAH MCK ABT SRCL JNJ
- 03/30/2020
|
Park Hotels & Resorts trading halted, volatility trading pause PK
- Park Hotels & Resorts trading halted, volatility trading pause PK
- 03/30/2020
|
FX Action: The dollar
- FX Action: The dollar
- 03/30/2020
|
Methanex downgraded to Market Perform from Outperform at Raymond James MEOH
- Methanex downgraded to Market Perform from Outperform at Raymond James Raymond James MEOH
- 03/30/2020
|
Raymond James likes Amgen in premarket analyst action
- BioSig Technologies (NASDAQ:BSGM) initiated with Buy rating and $9 (75% upside) price target at Roth Capital.Amgen (NASDAQ:AMGN) upgraded to Outperform with a $255 (29% upside) price target at Raymond
- 03/30/2020
|
CCL, RBS among premarket losers
- Arlington Asset Investment (NYSE:AI) -21% after suspending Q1 dividend.BGC Partners (NASDAQ:BGCP) -20% on dividend cut.Altimmune (NASDAQ:ALT) -15% on FY earnings.Arbutus Biopharma (NASDAQ:ABUS) -10% d
- 03/27/2020
|
NRZ, TLRY among premarket gainers
- Granite Point Mortgage Trust (NYSE:GPMT) +104% on suspending Q1 dividend in move to conserve cash.MFA Financial (NYSE:MFA) +75% on cancelling dividend.Wanda Sports Group Company (NASDAQ:WSG) +55% afte
- 03/26/2020
|
17 Healthcare Stocks Moving In Thursday's Pre-Market Session
- Gainers
• BioSig Technologies, Inc. (NASDAQ:BSGM) stock increased by 36.43% to $5.28 during Thursday's pre-market session.
• Cerecor, Inc. (NASDAQ:CERC) stock moved...
- 03/26/2020
|
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 6.38%
- U.S. stocks higher at close of trade; Dow Jones Industrial Average up 6.38%
- 03/26/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLabs, ...
- 02/28/2020
|
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm ...
- 02/25/2020
|
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
- 02/21/2020
|
